Assessing Meningococcal B Vaccine Strategies for Patients Without a Spleen

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the immune response and safety of three different strategies for administering Meningococcal B vaccines (Bexsero® and Trumenba®) in patients who have undergone splenectomy. It aims to determine the effectiveness of these vaccine strategies in asplenic individuals, who are at a higher risk for invasive infections. The study will involve administering the vaccines at three different time points and will also investigate how long the immune response lasts in this vulnerable population. The findings could provide critical data on the immunogenicity of these vaccines in asplenic patients, where current data is lacking.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female, \>=18 to \<=75 years old.
2. Asplenic patient (for at least 2 weeks) with Howell Jolly bodies visible on blood film
3. Splenectomy confirmed by consultation and/or hospitalization report or the ultrasound if it has been performed during the routine follow-up
4. Women of childbearing age must have an effective contraception during the first 9 months of the study.
5. Participants must give written consent prior to any trial procedure
6. Participants must be covered by social security regimen or equivalent.
7. Participants will be followed during the 4 years from the inclusion visit.

Exclusion Criteria:

1. History of meningococcal vaccination B.
2. History of anaphylaxis post vaccination.
3. Known allergy to any components (active substances or excipients) of both vaccines.
4. Patients who cannot stop antibiotics 3 days before blood collection.
5. Participants who have received any another vaccines within 4 weeks prior to immunization or who are planning to receive any vaccine within the first 7 months of the study (except the meningococcal ACWY vaccine, the anti-pneumococcal vaccine, the Haemophilus influenzae type B vaccine, the anti-Covid-19 vaccine), annual influenza vaccination which is permitted 2 weeks before and after each vaccination visit of the study and then allowed at any time during the study follow up).
6. Parenteral Ig within the 3 months prior to VS or planned during the study.
7. Chemotherapy agents within 6 months prior M0 or planning to take any during the study.
8. Steroids (\> 10mg/day; \> 14 days) within the month preceding M0 or planning to take any during the study.
9. Any pathology or condition that may impair the immune response, apart from splenectomy: immunosuppressive therapy in progress or in the 6 months prior to inclusion, hematopoietic stem cells allo / autograft, primary immunodeficiency, nephrotic syndrome, evolutive cancer, cirrhosis, known infection to HIV;
10. Thrombocytopenia or any coagulation disorder contra-indicating intramuscularly injections.
11. Pregnancy, breastfeeding or positive pregnancy test up to 7 months after inclusion.
12. Severe acute febrile illness within the week before inclusion.
13. Registration for any other clinical trial throughout the trial period except observational study.

Where it's running

• I-REIVAC/CIC1417 Cochin Hospital, AP-HP
  Paris, France Recruiting

Study contacts

• Principal investigator: Odile LAUNAY, MD,PhD — CIC 1417 Clinical Center Investigation
• Study coordinator: Odile LAUNAY, MD,PhD
• Email: odile.launay@aphp.fr
• Phone: +33(01)58 41 28 58

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Education to prevent infections after spleen removal

  See if a targeted educational program for adults who had their spleen removed improves vaccination uptake, awareness of infection risk, and continuity of care.

  Recruiting at 2 sites Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Lazio and 1 other locations · NCT07354893

• Apixaban for portal vein clots that appear more than a year after laparoscopic splenectomy

  This trial tests whether taking apixaban twice daily can treat portal vein blood clots that develop more than a year after laparoscopic splenectomy in people with cirrhosis.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07461545

• Apixaban for portal vein thrombosis occurring more than one year after laparoscopic splenectomy and azygoportal disconnection

  This trial will try whether taking apixaban 2.5 mg twice daily can treat portal vein clots that appear more than a year after laparoscopic splenectomy and azygoportal disconnection in people with cirrhosis.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07461532

• Italian questionnaire to measure knowledge and vaccination attitudes in people without a spleen

  This project will test a new Italian questionnaire to measure how much people without a spleen know about infection prevention and vaccination.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Lazio · NCT07428005

• Laparoscopic partial removal of the spleen for hypersplenism in cirrhosis.

  This test tries whether removing part of the spleen by laparoscopy improves immune function and recovery in people with cirrhosis and hypersplenism.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07205471

• Screening for ASMD in people with diffuse interstitial lung disease

  This study tests a screening algorithm to see if people with diffuse ILD, who may have ASMD, actually have the disease by measuring acid sphingomyelinase activity and LysoSM in a 200-person cohort.

  Recruiting Groupe Hospitalier Diaconesses Croix Saint-Simon · Paris · NCT06869499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.